Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine

Status:
Active, not recruiting

Trial end date:
2022-01-29

Target enrollment:

Participant gender:

This trial is to determine whether BHV3000 (rimegepant) 75mg is safe and effictive as a treatment for acute migraine in Chinese and Korean patients

Phase 3

Biohaven Pharmaceuticals, Inc.

BioShin Limited